Jenburkt Pharmaceuticals Ltd Share Price (524731)
as on
| Source : BSE
Jenburkt Pharmaceuticals Ltd Stock Performance
as on August 14, 2025 at 4:01 PM IST
Day's Low
Day's High
₹1,117.5₹1,183.95
5.30%
Downside
0.33%
Upside
52 Week's Low
52 Week's High
₹873.3₹1,41025.99%
Downside
19.49%
Upside
| Market Stats | |
| Previous Close | ₹1,148.90 |
| Open | ₹1,157.45 |
| Volume | 1,638.00 |
| Upper Circuit | ₹1,378.65 |
| Lower Circuit | ₹919.15 |
| Day's Low | ₹1,117.5 |
| Day's High | ₹1,183.95 |
| 52 Week Low | ₹873.3 |
| 52 Week High | ₹1,410 |
| Returns % | |
| 1 Month Return | -10.01 % |
| 3 Month Return | + 6.21 % |
| 1 Year Return | + 25.15 % |
| 3 Year Return | + 105.36 % |
| 5 Year Return | + 174.07 % |
Jenburkt Pharmaceuticals Ltd Stock Fundamentals & Key Indicators
Check Jenburkt Pharmaceuticals Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹516.05 Cr
Return on Equity (ROE)
20.25
PE Ratio (TTM)
0Return on capital employed (ROCE)
27.18
Beta (LTM)
1.05
P/B Ratio
2.6
Dividend Yield
0PEG Ratio
0Quarterly Earnings Growth YOY
4.99
EPS (TTM)
0Sector
Pharmaceuticals
Book Value
0Technical Analysis
Bearish
View Technical Analysis
Jenburkt Pharmaceuticals Ltd Stock's Interest Amongst Investors
Jenburkt Pharmaceuticals Ltd Financial Results
Get the annual and quarterly financial summary of Jenburkt Pharmaceuticals Ltd, including revenue, profit, loss and more.
Jenburkt Pharmaceuticals Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Jenburkt Pharmaceuticals Ltd.
Jenburkt Pharmaceuticals Ltd Earnings Results
Jenburkt Pharmaceuticals Ltd’s net profit jumped 4.99% since last year same period to ₹7.79Cr in the Q1 2025-2026. On a quarterly growth basis, Jenburkt Pharmaceuticals Ltd has generated -8.78% fall in its net profits since last 3-months.
Read More about Earnings ResultsJenburkt Pharmaceuticals Ltd Dividends May,2025
In the quarter ending March 2025, Jenburkt Pharmaceuticals Ltd has declared dividend of ₹18.00 per share on 20 May 2025 - translating a dividend yield of 2.82%.
Read More about Dividends
Jenburkt Pharmaceuticals Ltd Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Jenburkt Pharmaceuticals Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.67% | ||
| Foreign Institutions | 0% | 0.00 | |
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 53.22% | 0.02 | |
| Others | 0.12% | 0.00 |
Jenburkt Pharmaceuticals Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Jenburkt Pharmaceuticals Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| NA | 516.05 | 34.81% | 0.00 | 32 | 151 | |
| NA | 978.45 | 47.28% | 0.75 | 10 | 257 | |
| NA | 41.50 | 5.58% | 0.00 | 1 | 221 | |
| NA | 55.40 | 30.12% | 0.00 | 5 | 37 | |
| NA | 270.34 | 1.26% | 0.00 | 9 | 162 |
Insights on Jenburkt Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 53.20% to 53.22% in Jun 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 year, Jenburkt Pharma stock has moved up by 29.0%
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 130.2% return, outperforming this stock by 20.3%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 32.3% return, outperforming this stock by 3.3%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.68% to 46.67% in Jun 2025 quarter
About Jenburkt Pharmaceuticals Ltd
Founders of the company, the Bhuta family, help maintain the core values of Jenburkt, as over 35 years of experience in the pharmaceutical industry ensures that its products meet the highest standards of quality and efficiency. With a stellar history and experience in the field, Jenburkt continues to serve the healthcare industry with its unique solutions and services.
Revenue: ₹35.53Cr as on June 2025 (Q1 FY26)
Net Profit: ₹7.79Cr as on June 2025 (Q1 FY26)
Chairperson Name: Ashish U Bhuta
| Organisation | Jenburkt Pharmaceuticals Ltd |
| Industry | Pharmaceuticals |
| CEO | Ashish U Bhuta |
| E-voting on shares | Click here to vote |
FAQs
What is Jenburkt Pharmaceuticals Ltd share price today?
Jenburkt Pharmaceuticals Ltd share price today stands at ₹1180, Open: ₹1157.45, Previous Close: ₹1148.9, High: ₹1183.95, Low: ₹1117.5, 52 Week High: ₹1410, 52 Week Low: ₹873.3 as on .
How to buy Jenburkt Pharmaceuticals Ltd shares ?
To buy Jenburkt Pharmaceuticals Ltd shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for 524731 or Jenburkt Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Jenburkt Pharmaceuticals Ltd shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Jenburkt Pharmaceuticals Ltd?
Today's traded volume of Jenburkt Pharmaceuticals Ltd is 1,638.00. Which means that 1,638.00 shares of Jenburkt Pharmaceuticals Ltd were bought and sold on the stock market during today's trading session.
What is Jenburkt Pharmaceuticals Ltd's market cap today?
Today's market capitalisation of Jenburkt Pharmaceuticals Ltd is ₹516.05 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd’s 52 week high is ₹1410 and 52 week low is ₹873.3. The current share price of Jenburkt Pharmaceuticals Ltd is ₹1180, which is -16.31% down from its 52 week high and 35.12% up from its 52 week low.